Key Points

  • Moderna's investigational mRNA vaccine (mRNA-1345) for respiratory syncytial virus (RSV) was 83.7% effective in a late-stage trial in preventing at least two symptoms in adults aged 60 and older.
  • The company intends to submit its RSV vaccine candidate for regulatory approval in the first half of 2023.
  • RSV is a highly contagious seasonal respiratory virus and currently, there are no approved vaccines for preventing it.
  • Moderna's RSV vaccine for adults could considerably boost the company's revenue, with the global market estimated to be worth over $10 billion.
  • Shares of Moderna stock (MRNA) were up 6.5% in Tuesday's extended trading session following the announcement.

Moderna the biotechnology company has announced that its investigational mRNA vaccine (mRNA-1345) for respiratory syncytial virus (RSV) was 83.7% effective in a late-stage trial in preventing at least two symptoms in adults aged 60 and older. This news has caused MRNA stock to rise 6.5% in Tuesday's extended trading session.

This announcement comes as a relief for Moderna Stock, as investors have been concerned about the waning demand for COVID-19 treatments. If approved, Moderna's RSV vaccine for adults could considerably boost the company's revenue. According to Cowen analyst Tyler Van Buren, the RSV vaccine market could be worth over $10 billion globally, half of which is estimated to be generated in the U.S.

Image Description

Currently, there are no approved vaccines for preventing RSV. Moderna is competing with Pfizer and GSK to get its RSV vaccine approved. Pfizer and GSK filed applications for U.S. regulatory approval in late 2022. However, Moderna's announcement of the vaccine's efficacy in preventing disease in older adults sets it apart from its competitors.

Moderna Trials

Moderna rose to fame by developing a COVID-19 vaccine based on its mRNA technology. The company generated billions of dollars from COVID-19 vaccine sales. However, with the COVID-19 pandemic slowly coming under control, Moderna has been looking for new opportunities to continue its growth. The RSV vaccine is a promising opportunity for the company.

The Street's Moderate Buy consensus rating for Moderna stock is based on seven Buys and eight Holds. The average MRNA stock price target of $227.58 implies 19.4% upside potential. Shares have advanced 2.2% over the past year. With the announcement of the vaccine's efficacy, it is likely that MRNA stock will continue to rise in the coming weeks and months.

Moderna after Covid

It is worth noting that Moderna intends to submit its RSV vaccine candidate for regulatory approval in the first half of 2023.

This could bring a big boost for the company stock, making it a strong player in the vaccine market. The company is also working on other potential vaccines, such as for the human metapneumovirus, which could bring in even more revenue for the company.

Moderna's announcement of the efficacy of its RSV vaccine is a big positive for the company, and it could bring in a significant amount of revenue in the coming years. The company is also working on other potential vaccines, which could bring in even more revenue, making it a strong player in the vaccine market. This news is likely to drive MRNA stock higher in the coming weeks and months.



About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $40.6B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA